BioNTech’s ASCO Pivot: A $19.6 Billion War Chest Meets a 47.9% Response Rate

BioNTech steps onto the stage at the ASCO Annual Meeting in Chicago this week carrying more than clinical data — it brings a corporate transformation that is already reshaping its cost base and cash allocation. With $19.6 billion in the bank and a $1 billion share buyback program running, the Mainz-based group is pouring resources into oncology while simultaneously slashing 1,860 jobs across its COVID-era production sites in Idar-Oberstein, Marburg, Singapore and at partner CureVac. The restructuring is expected to deliver roughly $585 million in annual savings by 2029, funds the company plans to funnel into commercializing a cancer portfolio that has yet to produce a single approved product.

That portfolio took center stage at ASCO, where BioNTech disclosed results from a phase 2 cohort of 145 patients with HER2-positive advanced endometrial carcinoma. The antibody-drug conjugate Trastuzumab Pamirtecan, developed with partner DualityBio, generated a confirmed objective response rate of 47.9 percent and a median progression-free survival of 8.1 months. The FDA had already granted both fast-track and breakthrough therapy designations in 2023. BioNTech and DualityBio intend to file a Biologics License Application with the U.S. regulator this year, pending feedback; in China, the corresponding application has already been accepted for review.

The ASCO presentation is just one piece of a broader clinical push. BioNTech is running more than 25 phase 2 and phase 3 studies, including 13 pivotal trials. Five new pivotal studies for the immunomodulator Pumitamig recently kicked off, targeting triple-negative breast cancer, MSS colorectal, gastric, and two non-small cell lung cancer settings. Additional phase 3 interim readouts are expected before the end of the year.

Should investors sell immediately? Or is it worth buying BioNTech?

Analysts have taken note of the gathering momentum. Canaccord Genuity reaffirmed its buy rating on May 28, following a cut in its price target from $171 to $158 earlier in the month. Wells Fargo also maintained its buy call on May 22. Both see the ASCO data dump as a potential catalyst that could validate BioNTech’s shift from pandemic vaccine maker to oncology player.

The company’s vaccine business, meanwhile, continues to provide a stable foundation. A study published May 28 in Nature Communications confirmed the enduring efficacy of the BioNTech-Pfizer shot BNT162b2 across various clinical settings, while an FDA advisory committee has recommended the COVID-19 vaccine composition for the 2026/2027 season, setting clear regulatory parameters for the autumn campaigns.

On the trading floor, the stock is hovering around €82, roughly 20 percent below its 52-week high of nearly €102. Technically, it sits right on its 50-day moving average but remains well below the 200-day average near €86. The March low of €72.50 has held, but a sustained uptrend has yet to materialize. Revenue guidance for 2026 stands at $2.3 billion to $2.6 billion, a range the company confirmed alongside its cost-cutting announcement. Whether the oncology pipeline can lift the share price above that 200-day line depends on whether the ASCO data — and the upcoming regulatory filings — convince the market that BioNTech’s mRNA expertise translates beyond infectious diseases.

Ad

BioNTech Stock: New Analysis - 29 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH’S | boerse | 69443242 |